Data from flow cytometric analysis supported this observation where TMZ-resistant GBM samples contained a significantly higher percentage of CD133+ cells as compared to their TMZ-sensitive counterparts (Fig. 2d). This evidence concerns the gene PROM1 and glioblastoma.